rVSV-ΔG-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk/benefit assessment.

Monath TP, Fusco J, Erbelding E, Kemp T, Heppner DG, DeVries M, Nichols R, Crowell JD, Scappaticci K, Pullano TG, Feldmann H, Feldmann F, Wellman ER, Farnon EC, Chen RT, Karuna S, Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO)

Open source

DOI: 10.1016/j.vaccine.2026.129113
Published: 2026 Dec 20
Container: Vaccine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.vaccine.2026.129113,
  title = {rVSV-ΔG-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk/benefit assessment.},
  author = {Monath TP and Fusco J and Erbelding E and Kemp T and Heppner DG and DeVries M and Nichols R and Crowell JD and Scappaticci K and Pullano TG and Feldmann H and Feldmann F and Wellman ER and Farnon EC and Chen RT and Karuna S and Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO)},
  year = {2026},
  journal = {Vaccine},
  doi = {10.1016/j.vaccine.2026.129113},
  url = {https://doi.org/10.1016/j.vaccine.2026.129113}
}

RIS

TY  - JOUR
TI  - rVSV-ΔG-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk/benefit assessment.
AU  - Monath TP
AU  - Fusco J
AU  - Erbelding E
AU  - Kemp T
AU  - Heppner DG
AU  - DeVries M
AU  - Nichols R
AU  - Crowell JD
AU  - Scappaticci K
AU  - Pullano TG
AU  - Feldmann H
AU  - Feldmann F
AU  - Wellman ER
AU  - Farnon EC
AU  - Chen RT
AU  - Karuna S
AU  - Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO)
PY  - 2026
JO  - Vaccine
DO  - 10.1016/j.vaccine.2026.129113
UR  - https://doi.org/10.1016/j.vaccine.2026.129113
ER  -

APA

TP, M., J, F., E, E., T, K., DG, H., M, D., R, N., JD, C., K, S., TG, P., H, F., F, F., ER, W., EC, F., RT, C., S, K., & (BRAVATO), B. C. B. A. O. V. B. T. (2026). rVSV-ΔG-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk/benefit assessment.. Vaccine. https://doi.org/10.1016/j.vaccine.2026.129113

Source records

pubmed · retrieved 2026-11-11T03:21:37.798Z